The Humira Drug Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Humira Drug Market:
https://www.thebusinessresearchcompany.com/report/humira-drug-global-market-report
According to The Business Research Company’s Humira Drug Global Market Report 2024, The humira drug market size has grown strongly in recent years. It will grow from $9.19 billion in 2023 to $9.86 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to introduction of biologics, biotechnology advancements, patient demand for effective treatments, physician adoption and prescribing patterns.
The humira drug market size is expected to see strong growth in the next few years. It will grow to $13.05 billion in 2028 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to biosimilar market entry, healthcare policy changes, focus on cost-effectiveness, research and development investments, precision medicine and personalized treatments. Major trends in the forecast period include real-world evidence generation, expanded use in pediatric populations, shift towards self-administered medications, value-based pricing models, targeted therapies development.
A rise in the incidence rate of autoimmune disease is expected to propel the growth of the humira drug market going forward. Autoimmune disease refers to a type of disease in which the body’s immune system attacks and destroys healthy tissues and cells in the body. Humira drug is used to treat pain and inflammation caused by various autoimmune diseases, as a result, the rise in the incidence rate of autoimmune diseases increases the demand for humira drug. For instance, in July 2021, according to Cleveland Clinics, a US-based non-profit academic medical center, 1 in 15 people in the U.S. have an autoimmune disease. Further, one million people in the U.S. are suffering from lupus and 1.4 million have Crohn’s disease or ulcerative colitis respectively. Therefore, the rise in the incidence rate of autoimmune disease will drive the HUMIRA drug market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=11934&type=smp
The humira drug market covered in this report is segmented –
1) By Type: Humira Syringe, Humira Pen
2) By Application: Ankylosing Spondylitis, Rheumatoid Arthritis, Crohn’s Disease, Other Applications
3) By End-Users: Hospitals, Specialty Clinics, Other End-Users
Product innovations are a key trend in the humira drug market. Major companies in the humira drug market are developing new biologics and biosimilars to sustain their position in the market. For instance, in April 2023, Sandoz, a Switzerland-based pharmaceutical company introduced Biosimilar Hyrimoz (adalimumab), a citrate-free high-concentration formulation (HCF) approved by the European Commission. The adalimumab citrate-free HCF (100 mg/mL) formulation provides a 50 % reduction in injection volume and decreases the number of injections required for patients opting for 80 mg/mL or higher dosing. This is applicable to various diseases such as rheumatic diseases, Crohn’s disease, and others with enhanced familiar experience.
The humira drug market report table of contents includes:
1. Executive Summary
2. Humira Drug Market Characteristics
3. Humira Drug Market Trends And Strategies
4. Humira Drug Market – Macro Economic Scenario
5. Global Humira Drug Market Size and Growth
.
.
.
26. South America Humira Drug Market
27. Brazil Humira Drug Market
28. Middle East Humira Drug Market
29. Africa Humira Drug Market
30. Humira Drug Market Competitive Landscape And Company Profiles
Top Major Players:
- Pfizer Inc
- Merck & Co. Inc
- AbbVie Inc
- Novartis AG
- Fresenius Kabi AG
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
